Edgewise Therapeutics CMO sells $202k in company stock

In a recent transaction, Joanne M. Donovan, the Chief Medical Officer (CMO) of Edgewise Therapeutics, Inc. (NASDAQ:EWTX), sold shares of the company's common stock. The sale, which took place on September 20, 2024, involved a total of 7,162 shares at an average price of $28.2886 per share, resulting in an aggregate sale amount of approximately $202,602.

Investors tracking insider transactions may note that the price per share for this sale fell within a narrow range of $28.28 to $28.29. The specific details regarding the number of shares sold at each price point within this range are available upon request, as per the footnotes in the SEC filing.

Following the sale, Donovan's remaining holdings in Edgewise Therapeutics include 14,538 shares of common stock. It's worth mentioning that this total includes 1,803 shares that were acquired on May 15, 2024, under the company's 2021 Employee Stock Purchase Plan.

The transaction reflects the ongoing financial activities of company insiders, which are routinely disclosed to the public through SEC filings. Edgewise Therapeutics, based in Boulder, Colorado, operates in the pharmaceutical preparations industry and is known for its focus on precision medicine for musculoskeletal diseases.

Investors and analysts often review such insider transactions as part of their due diligence, considering them alongside other factors when evaluating a company's financial health and future prospects.



In other recent news, Edgewise Therapeutics has been the focus of several noteworthy developments. The biopharmaceutical company saw promising results from Phase 1 and Phase 2 trials of its heart disease drug, EDG-7500, which demonstrated tolerability and significant reductions in left ventricular outflow tract gradients in patients with Hypertrophic Cardiomyopathy. RBC Capital Markets raised its price target for Edgewise Therapeutics from $32.00 to $42.00, maintaining an Outperform rating, while Truist Securities raised its price target from $25.00 to $33.00, keeping a Buy rating. Both firms cited the potential of the company's HCM program as a reason for their optimism.

In addition to these developments, Piper Sandler maintained its Overweight rating on Edgewise, emphasizing the upcoming milestones such as the Phase 1 trials for EDG-7500. Edgewise Therapeutics also approved the 2024 Inducement Equity Incentive Plan, reserving 2 million shares of common stock for new equity awards, indicating its commitment to innovation and talent acquisition.

These recent developments highlight Edgewise Therapeutics' ongoing efforts to advance its drug development pipeline and bring new treatment options to the market.
InvestingPro Insights


As investors digest the recent insider transaction at Edgewise Therapeutics, Inc. (NASDAQ:EWTX), it's important to consider the company's broader financial context provided by InvestingPro. With a market capitalization of $2.43 billion, the company's financial health can be further understood by examining key metrics and insights.

InvestingPro data shows that Edgewise Therapeutics holds a negative P/E ratio of -17.06, reflecting its current lack of profitability. This aligns with the InvestingPro Tip that analysts do not anticipate the company will be profitable this year. In addition, the company's operating income stands at an adjusted -136.17 million USD over the last twelve months as of Q2 2024, reinforcing the challenges it faces in generating profit.

Despite these challenges, Edgewise Therapeutics has demonstrated significant price returns, with a one-week total return of 35.92% and a one-year total return of 337.84%. This robust performance is also highlighted by InvestingPro Tips, which note a strong return over the last month and three months, as well as a large price uptick over the last six months.

Lastly, it's noteworthy that Edgewise Therapeutics holds more cash than debt on its balance sheet and that its liquid assets exceed short-term obligations, providing it with a degree of financial flexibility. These insights, among others, are part of the comprehensive analysis available on InvestingPro, which includes additional tips to help investors make informed decisions. For more detailed insights and tips on Edgewise Therapeutics, investors can refer to the full list of 11 InvestingPro Tips at https://www.investing.com/pro/EWTX.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com